LncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206/SLC7A11 axis in osteosarcoma cells

The most prevalent form of primary osseous malignant tumor in adolescents and children is osteosarcoma (OS). A combination of surgery and neoadjuvant/post-surgery chemotherapy is currently the standard therapy. While the chemoresistance associated with OS generally leads to poor efficacy of therapeutic agents, the relevant molecular interaction is still elusive. Here, the lncRNA (long non-coding RNA) SNHG14 was found to be significantly upregulated in the nutlin3a-resistant OS cell line NR-SJSA1 and contributes to treatment resistance by suppressing ferroptosis. In NR-SJSA1 cells, knockdown of LncRNA SNHG14 resulted in a reversal of drug resistance and activation of ferroptosis, which disappeared when ferrostatin-1, a ferroptosis inhibitor, was added. Mechanistically, lncRNA SNHG14 targeted and down-regulated the expression of miR-206, further affecting the common ferroptosis inhibitor SLC7A11, and preventing NR-SJSA1 cells from undergoing ferroptosis. In conclusion, our findings highlight the involvement of lncRNA SNHG14 in ferroptosis and chemotherapy resistance of nutlin3a-resistant NR-SJSA1 cells, thus shedding new insight on how to overcome drug resistance in osteosarcoma cells and improve treatment efficacy.

Automated summary

Osteosarcoma (OS) is the most common primary osseous malignant tumor in adolescents and children. The standard therapy involves surgery combined with neoadjuvant/post-surgery chemotherapy, but chemoresistance often leads to poor efficacy. In this study, the upregulation of lncRNA SNHG14 was found to contribute to treatment resistance by suppressing ferroptosis in a nutlin3a-resistant OS cell line. Knockdown of lncRNA SNHG14 reversed drug resistance and activated ferroptosis, indicating its role in chemotherapy resistance and ferroptosis inhibition. Targeting lncRNA SNHG14 may provide a new approach to overcome drug resistance and improve treatment efficacy in osteosarcoma.